Dianthus Therapeutics IncNASDAQ:DNTH
- LAST PRICE22.2100
- TODAY'S CHANGE (%)1.9400 (9.5708%)
- Bid / Lots22.0800/ 8
- Ask / Lots22.2200/ 1
- Open / Previous Close20.3700 / 20.2700
- Day Range
- 52 Week Range
- Volume184,443
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | DNTH |
|---|---|---|
| 09:32 ET | 1623 | 20.5 |
| 09:35 ET | 100 | 20.62 |
| 09:37 ET | 200 | 20.45 |
| 09:39 ET | 501 | 20.46 |
| 09:42 ET | 100 | 20.8 |
| 09:44 ET | 100 | 20.8 |
| 09:46 ET | 500 | 20.8 |
| 09:48 ET | 1165 | 20.76 |
| 09:50 ET | 2395 | 20.995 |
| 09:51 ET | 100 | 21.25 |
| 09:53 ET | 1700 | 21.26 |
| 09:55 ET | 500 | 21.415 |
| 10:00 ET | 600 | 21.35 |
| 10:02 ET | 2573 | 21.07 |
| 10:04 ET | 846 | 21.17 |
| 10:09 ET | 100 | 21.31 |
| 10:11 ET | 200 | 21.31 |
| 10:13 ET | 100 | 21.31 |
| 10:15 ET | 100 | 21.305 |
| 10:18 ET | 100 | 21.31 |
| 10:22 ET | 200 | 21.32 |
| 10:24 ET | 100 | 21.47 |
| 10:26 ET | 100 | 21.46 |
| 10:27 ET | 100 | 21.41 |
| 10:31 ET | 100 | 21.4 |
| 10:33 ET | 100 | 21.4 |
| 10:38 ET | 100 | 21.255 |
| 10:42 ET | 500 | 21.62 |
| 10:44 ET | 100 | 21.61 |
| 10:45 ET | 1300 | 21.49 |
| 10:47 ET | 3200 | 21.49 |
| 10:49 ET | 800 | 21.49 |
| 10:51 ET | 160 | 21.48 |
| 10:54 ET | 368 | 21.655 |
| 10:56 ET | 700 | 21.6 |
| 11:00 ET | 2766 | 21.56 |
| 11:07 ET | 1600 | 21.56 |
| 11:09 ET | 800 | 21.595 |
| 11:23 ET | 200 | 21.7 |
| 11:27 ET | 761 | 21.7999 |
| 11:30 ET | 2100 | 21.635 |
| 11:34 ET | 405 | 21.63 |
| 11:36 ET | 1400 | 21.525 |
| 11:38 ET | 1489 | 21.555 |
| 11:39 ET | 17911 | 21.54 |
| 11:41 ET | 100 | 21.54 |
| 11:43 ET | 330 | 21.64 |
| 11:45 ET | 400 | 21.54 |
| 11:48 ET | 400 | 21.54 |
| 11:50 ET | 100 | 21.54 |
| 11:52 ET | 100 | 21.54 |
| 11:56 ET | 200 | 21.6 |
| 12:01 ET | 200 | 21.55 |
| 12:03 ET | 1804 | 21.37 |
| 12:08 ET | 180 | 21.26 |
| 12:14 ET | 289 | 21.3223 |
| 12:15 ET | 600 | 21.26 |
| 12:24 ET | 346 | 21.2864 |
| 12:26 ET | 500 | 21.4 |
| 12:30 ET | 300 | 21.315 |
| 12:37 ET | 100 | 21.305 |
| 12:39 ET | 200 | 21.35 |
| 12:42 ET | 1100 | 21.4 |
| 12:44 ET | 1503 | 21.29 |
| 12:46 ET | 200 | 21.285 |
| 12:50 ET | 300 | 21.29 |
| 12:51 ET | 500 | 21.4 |
| 12:55 ET | 100 | 21.38 |
| 12:57 ET | 100 | 21.3 |
| 01:00 ET | 3823 | 21.37 |
| 01:02 ET | 600 | 21.35 |
| 01:04 ET | 1400 | 21.36 |
| 01:06 ET | 400 | 21.36 |
| 01:08 ET | 7000 | 21.36 |
| 01:09 ET | 600 | 21.36 |
| 01:11 ET | 400 | 21.36 |
| 01:13 ET | 600 | 21.352 |
| 01:18 ET | 100 | 21.45 |
| 01:20 ET | 200 | 21.365 |
| 01:22 ET | 1000 | 21.365 |
| 01:24 ET | 100 | 21.355 |
| 01:27 ET | 300 | 21.43 |
| 01:36 ET | 228 | 21.47 |
| 01:38 ET | 400 | 21.57 |
| 01:40 ET | 25900 | 21.51 |
| 01:44 ET | 400 | 21.51 |
| 01:45 ET | 2978 | 21.39 |
| 01:47 ET | 426 | 21.56 |
| 01:49 ET | 2163 | 21.555 |
| 01:51 ET | 100 | 21.5025 |
| 02:00 ET | 506 | 21.45 |
| 02:07 ET | 21783 | 21.665 |
| 02:09 ET | 669 | 21.76 |
| 02:12 ET | 3150 | 21.97 |
| 02:16 ET | 2936 | 21.935 |
| 02:18 ET | 700 | 21.925 |
| 02:20 ET | 3700 | 22 |
| 02:21 ET | 1300 | 21.9 |
| 02:23 ET | 2812 | 21.98 |
| 02:25 ET | 687 | 22.05 |
| 02:34 ET | 1300 | 22.15 |
| 02:36 ET | 100 | 22.21 |
Nov 11, 2024
DJ Dianthus Therapeutics Price Target Maintained With a $40.00/Share by HC Wainwright & Co., from 10:24AM ET on Monday Nov 11, 2024 by Dow Jones
10:24AM ET on Monday Nov 11, 2024 by Dow JonesDJ Dianthus Therapeutics Is Maintained at Outperform by Oppenheimer, from 8:30AM ET on Monday Nov 11, 2024 by Dow Jones
8:30AM ET on Monday Nov 11, 2024 by Dow Jones
Nov 8, 2024
DJ Dianthus Therapeutics Is Maintained at Outperform by Raymond James, from 12:55PM ET on Friday Nov 08, 2024 by Dow Jones
12:55PM ET on Friday Nov 08, 2024 by Dow Jones
Nov 7, 2024
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results, from 4:01PM ET on Thursday Nov 07, 2024 by Dow Jones
4:01PM ET on Thursday Nov 07, 2024 by Dow JonesPress Release: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results, from 4:01PM ET on Thursday Nov 07, 2024 by Dow Jones
4:01PM ET on Thursday Nov 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Dianthus Therapeutics Inc | 599.9M | -8.9x | --- |
Altimmune Inc | 597.4M | -5.6x | --- |
Mineralys Therapeutics Inc | 590.3M | -3.8x | --- |
Tourmaline Bio Inc | 582.6M | -14.0x | --- |
Stoke Therapeutics Inc | 596.9M | -5.5x | --- |
Corvus Pharmaceuticals Inc | 559.2M | -9.8x | --- |
Company Information
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to advancing antibody complement therapeutics to treat severe autoimmune diseases. The Company is dedicated to designing and delivering monoclonal antibodies with improved selectivity and potency. The Company has initiated a Phase 2 trial of DNTH103, a potential active C1s inhibitor, in generalized Myasthenia Gravis and plans to initiate additional Phase 2 trials in other neuromuscular indications, including Multifocal Motor Neuropathy and Chronic Inflammatory Demyelinating Polyneuropathy. Its product candidate, DNTH103, is a clinical-stage, highly potent, highly selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of the C1s complement protein. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile.
Contact Information
- Headquarters
- 7 Times Square, 43Rd FloorNEW YORK, NY, United States 10036
- Phone
- 929-999-4055
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Leon Moulder
- President, Chief Executive Officer, Director
- Marino Garcia
- Chief Financial Officer, Chief Business Officer Treasurer
- Ryan Savitz
- Senior Vice President, General Counsel, Company Secretary
- Adam Veness
- Chief Accounting Officer
- Edward Carr
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $599.9M |
|---|---|
Revenue (TTM) | $5.4M |
Shares Outstanding | 29.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.76 |
EPS | $-2.49 |
Book Value | $11.40 |
P/E Ratio | -8.9x |
Price/Sales (TTM) | 111.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,544.99% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
